VOR VS PRQR Stock Comparison
Performance
VOR10/100
10/100
VOR returned -61.10% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.
PRQR100/100
100/100
PRQR returned 53.12% in the last 12 months. Based on SPY's performance of 13.09%, its performance is above average giving it a score of 100 of 100.
Technicals
VOR10/100
10/100
VOR receives a 10 of 100 based on 14 indicators. 0 are bullish, 12 are bearish.
PRQR61/100
61/100
PRQR receives a 60 of 100 based on 14 indicators. 8 are bullish, 5 are bearish.
Earnings
VOR10/100
10/100
VOR has missed earnings 6 times in the last 20 quarters.
PRQR10/100
10/100
PRQR has missed earnings 9 times in the last 20 quarters.
Profit
VOR10/100
10/100
Out of the last 16 quarters, VOR has had 0 profitable quarters and has increased their profits year over year on 0 of them.
PRQR10/100
10/100
Out of the last 20 quarters, PRQR has had 0 profitable quarters and has increased their profits year over year on 0 of them.
Volatility
VOR43/100
43/100
VOR has had a lower than average amount of volatility over the last 12 months giving it a score of 42 of 100.
PRQR64/100
64/100
PRQR has had a higher than average amount of volatility over the last 12 months giving it a score of 64 of 100.
Analyst Price Targets
VOR
"Analyst Price Targets" not found for VOR
PRQR75/100
75/100
4 analysts offer 12-month price targets for PRQR. Together, they have an average target of 4, the most optimistic target put PRQR at 5 within 12-months and the most pessimistic has PRQR at 2.
Sentiment
VOR
"Sentiment" not found for VOR
PRQR72/100
72/100
PRQR had a bullish sentiment score of 72.23% across Twitter and StockTwits over the last 12 months. It had an average of 3.77 posts, 0.92 comments, and 4.23 likes per day.
All score calculations are broken down here to help you make more informed investing decisions
Vor Biopharma Inc. Common Stock Summary
Nasdaq / VOR
Healthcare
Biotechnology
Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
ProQR Therapeutics N.V. Ordinary Shares Summary
Nasdaq / PRQR
Healthcare
Biotechnology
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome. The company also engages in the developing of Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Compare Similar Companies
Compare VOR to other companies in the same or a similar industry.